论文部分内容阅读
目的探讨血塞通注射液联合依帕司他治疗早期糖尿病肾病的临床疗效。方法选取2014年7月—2015年12月河北冶建医院收治的早期糖尿病肾病患者78例,采用随机数字表法将其分为对照组40例和观察组38例。对照组给予依帕司他片治疗,观察组在对照组基础上给予血塞通注射液。比较两组患者治疗前后空腹血糖(FBG)、餐后2h血糖(2h PG)、糖化血红蛋白(Hb A_(1c))、血尿素氮(BUN)、血肌酐(Scr);24h尿微量清蛋白(UALB);留取晨尿,采用苦味酸法监测尿肌酐(UCr),采用免疫透射比浊法检测β_2微球蛋白(β_2-MG);及两组不良反应发生情况。结果治疗前两组患者FBG、2h PG、Hb A_(1c)水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血糖FBG、2h PG、Hb A_(1c)水平低于对照组,差异有统计学意义(P<0.05)。治疗前两组患者BUN、Scr、UALB、β_2-MG/Cr比较,差异无统计学意义(P>0.05);治疗后观察组患者BUN、Scr、UALB、β_2-MG/Cr水平低于对照组,差异有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论血塞通注射液联合依帕司他治疗早期糖尿病肾病的临床疗效明显,可降低血糖并改善肾功能,且不良反应少。
Objective To investigate the clinical efficacy of Xuesaitong injection combined with epalrestat in the treatment of early diabetic nephropathy. Methods From July 2014 to December 2015, 78 patients with early diabetic nephropathy admitted to Hebei Jianshe Hospital were randomly divided into control group (n = 40) and observation group (n = 38) using random number table. The control group was treated with epalrestat tablets, and the observation group was given Xuesaitong injection on the basis of the control group. The levels of fasting blood glucose (FBG), postprandial 2h PG, Hb A 1c, BUN, Scr and 24h urine microalbuminuria Urine creatinine (UALB) was taken for morning urine. Urinary creatinine (UCr) was monitored by picric acid method. Β_2-MG was detected by immunoturbidimetry. Results There was no significant difference in FBG, 2h PG and Hb A 1c between the two groups before treatment (P> 0.05). After treatment, the levels of FBG, 2h PG and Hb A 1c in the observation group were lower than those in the control group Group, the difference was statistically significant (P <0.05). There was no significant difference in BUN, Scr, UALB and β_2-MG / Cr between the two groups before treatment (P> 0.05). After treatment, the levels of BUN, Scr, UALB and β_2-MG / Cr in the observation group were lower than those in the control group , The difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Xuesaitong injection combined with epalrestat in the treatment of early diabetic nephropathy obvious clinical curative effect, can reduce blood glucose and improve renal function, and less adverse reactions.